Try our beta test site
5 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND CC-122 [TREATMENT]
Show Display Options
Rank Status Study
1 Recruiting A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: Obinutuzumab;   Drug: CC-122
2 Recruiting A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: CC-122
3 Recruiting Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: CC-122;   Drug: CC-223;   Drug: Rituximab;   Drug: CC-292
4 Recruiting Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Conditions: Multiple Myeloma;   Lymphoma, Large B-Cell, Diffuse;   Pleiotropic Pathway Modifier;   Glioblastoma;   Lymphoma;   Primary Central Nervous System Lymphoma (PCNSL)
Intervention: Drug: CC-122
5 Recruiting A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: CC-122;   Drug: Ibrutinib;   Drug: Obinutuzumab

Study has passed its completion date and status has not been verified in more than two years.